These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 8789792)
41. Effects of two K+ channel openers, aprikalim and pinacidil, on hypoxic pulmonary vasoconstriction. Dumas JP; Dumas M; Sgro C; Advenier C; Giudicelli JF Eur J Pharmacol; 1994 Sep; 263(1-2):17-23. PubMed ID: 7821349 [TBL] [Abstract][Full Text] [Related]
42. Celiprolol: agonist and antagonist effects at cardiac beta 1- and vascular beta 2-adrenoceptors determined under in vivo conditions in the rat. Alvarez-Guerra M; Alda O; Garay RP Naunyn Schmiedebergs Arch Pharmacol; 1997 Jun; 355(6):689-98. PubMed ID: 9205952 [TBL] [Abstract][Full Text] [Related]
44. Cardiovascular effects after inhalation of large doses of albuterol dry powder in rats, monkeys, and dogs: a species comparison. Petruska JM; Beattie JG; Stuart BO; Pai S; Walters KM; Banks CM; Lulham GW; Mirro EJ Fundam Appl Toxicol; 1997 Nov; 40(1):52-62. PubMed ID: 9398487 [TBL] [Abstract][Full Text] [Related]
45. Hemodynamic and cardiac effects of BMS-180448, a novel K+ATP opener, in anesthetized dogs and isolated rat hearts. D'Alonzo AJ; Grover GJ; Darbenzio RB; Sewter JC; Hess TA; Dzwonczyk S; Sleph PG Pharmacology; 1996 Feb; 52(2):101-12. PubMed ID: 8851631 [TBL] [Abstract][Full Text] [Related]
46. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent. Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137 [TBL] [Abstract][Full Text] [Related]
47. Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs. Mizumura T; Nithipatikom K; Gross GJ Circulation; 1995 Sep; 92(5):1236-45. PubMed ID: 7648671 [TBL] [Abstract][Full Text] [Related]
48. Hemodynamic profile of SKP-450, a new potassium-channel activator. Lee BH; Yoo SE; Shin HS J Cardiovasc Pharmacol; 1998 Jan; 31(1):85-94. PubMed ID: 9456282 [TBL] [Abstract][Full Text] [Related]
49. Cetamolol: cardiovascular effects of a new cardioselective beta-adrenoceptor blocker possessing partial agonistic activity and lacking membrane-stabilizing activity. Beaulieu G; Grimes D; Muirhead C; Oshiro G Can J Physiol Pharmacol; 1984 Jun; 62(6):610-6. PubMed ID: 6146394 [TBL] [Abstract][Full Text] [Related]
50. Cardiovascular effects of YM-16151-4: a novel calcium entry blocking and selective beta 1-adrenoceptor blocking agent in rats and dogs. Uchida W; Shibasaki K; Matsuda Y; Asano M; Takenaka T J Cardiovasc Pharmacol; 1993 Aug; 22(2):247-52. PubMed ID: 7692165 [TBL] [Abstract][Full Text] [Related]
55. The inotropic and beta blocking effects of a chimeric molecule that putatively inhibits both type III phosphodiesterase and beta adrenoceptors in anesthetized dogs. Shaffer JE; Grizzle MK; Anderson DK; Wheeler TN J Pharmacol Exp Ther; 1993 Jun; 265(3):1105-12. PubMed ID: 8099617 [TBL] [Abstract][Full Text] [Related]
56. Effect of diabetes mellitus on response of the basilar artery to activation of ATP-sensitive potassium channels. Mayhan WG Brain Res; 1994 Feb; 636(1):35-9. PubMed ID: 8156408 [TBL] [Abstract][Full Text] [Related]
57. Mechanism of myocardial protection by isoflurane. Role of adenosine triphosphate-regulated potassium (KATP) channels. Kersten JR; Schmeling TJ; Hettrick DA; Pagel PS; Gross GJ; Warltier DC Anesthesiology; 1996 Oct; 85(4):794-807; discussion 27A. PubMed ID: 8873550 [TBL] [Abstract][Full Text] [Related]